Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate comprising a humanized anti-CD19 monoclonal antibody conjugated to...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Hamadani, Mehdi, Radford, John, Carlo-Stella, Carmelo, Caimi, Paolo F., Reid, Erin, O’Connor, Owen A., Feingold, Jay M., Ardeshna, Kirit M., Townsend, William, Solh, Melhem, Heffner, Leonard T., Ungar, David, Wang, Luqiang, Boni, Joseph, Havenith, Karin, Qin, Yajuan, Kahl, Brad S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2021
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138546/
https://ncbi.nlm.nih.gov/pubmed/33211842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007512
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak